HOspitalised Pneumonia Extended (HOPE) Study to reduce the long-term effects of childhood pneumonia: protocol for a multicentre, double-blind, parallel, superiority randomised controlled trial

Anne B Chang, Siew Moy Fong, Tsin Wen Yeo, Robert S Ware, Gabrielle B McCallum, Anna M Nathan, Mong H Ooi, Jessie de Bruyne, Catherine A Byrnes, Bilawara Lee, Nachal Nachiappan, Noorazlina Saari, Paul Torzillo, Heidi Smith-Vaughan, Peter S Morris, John W Upham, Keith Grimwood, Anne B Chang, Siew Moy Fong, Tsin Wen Yeo, Robert S Ware, Gabrielle B McCallum, Anna M Nathan, Mong H Ooi, Jessie de Bruyne, Catherine A Byrnes, Bilawara Lee, Nachal Nachiappan, Noorazlina Saari, Paul Torzillo, Heidi Smith-Vaughan, Peter S Morris, John W Upham, Keith Grimwood

Abstract

Introduction: Early childhood pneumonia is a common problem globally with long-term complications that include bronchiectasis and chronic obstructive pulmonary disease. It is biologically plausible that these long-term effects may be minimised in young children at increased risk of such sequelae if any residual lower airway infection and inflammation in their developing lungs can be treated successfully by longer antibiotic courses. In contrast, shortened antibiotic treatments are being promoted because of concerns over inducing antimicrobial resistance. Nevertheless, the optimal treatment duration remains unknown. Outcomes from randomised controlled trials (RCTs) on paediatric pneumonia have focused on short-term (usually <2 weeks) results. Indeed, no long-term RCT-generated outcome data are available currently. We hypothesise that a longer antibiotic course, compared with the standard treatment course, reduces the risk of chronic respiratory symptoms/signs or bronchiectasis 24 months after the original pneumonia episode.

Methods and analysis: This multicentre, parallel, double-blind, placebo-controlled randomised trial involving seven hospitals in six cities from three different countries commenced in May 2016. Three-hundred-and-fourteen eligible Australian Indigenous, New Zealand Māori/Pacific and Malaysian children (aged 0.25 to 5 years) hospitalised for community-acquired, chest X-ray (CXR)-proven pneumonia are being recruited. Following intravenous antibiotics and 3 days of amoxicillin-clavulanate, they are randomised (stratified by site and age group, allocation-concealed) to receive either: (i) amoxicillin-clavulanate (80 mg/kg/day (maximum 980 mg of amoxicillin) in two-divided doses or (ii) placebo (equal volume and dosing frequency) for 8 days. Clinical data, nasopharyngeal swab, bloods and CXR are collected. The primary outcome is the proportion of children without chronic respiratory symptom/signs of bronchiectasis at 24 months. The main secondary outcomes are 'clinical cure' at 4 weeks, time-to-next respiratory-related hospitalisation and antibiotic resistance of nasopharyngeal respiratory bacteria.

Ethics and dissemination: The Human Research Ethics Committees of all the recruiting institutions (Darwin: Northern Territory Department of Health and Menzies School of Health Research; Auckland: Starship Children's and KidsFirst Hospitals; East Malaysia: Likas Hospital and Sarawak General Hospital; Kuala Lumpur: University of Malaya Research Ethics Committee; and Klang: Malaysian Department of Health) have approved the research protocol version 7 (13 August 2018). The RCT and other results will be submitted for publication.

Trial registration: ACTRN12616000046404.

Keywords: children; clinical trials; pneumonia.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Overall schematic study design. ABs, antibiotics; CXR, chest X-ray; NPS, nasopharyngeal swab.

References

    1. WHO. Revised WHO classification and treatment of childhood pneumonia: WHO, 2014.
    1. Madhi SA, De Wals P, Grijalva CG, et al. . The burden of childhood pneumonia in the developed world: a review of the literature. Pediatr Infect Dis J 2013;32:e119–27. 10.1097/INF.0b013e3182784b26
    1. Chan JY, Stern DA, Guerra S, et al. . Pneumonia in childhood and impaired lung function in adults: a longitudinal study. Pediatrics 2015;135:607–16. 10.1542/peds.2014-3060
    1. Valery PC, Torzillo PJ, Mulholland K, et al. . Hospital-based case-control study of bronchiectasis in indigenous children in Central Australia. Pediatr Infect Dis J 2004;23:902–8. 10.1097/01.inf.0000142508.33623.2f
    1. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733–43. 10.1016/S0140-6736(09)61303-9
    1. McCallum GB, Binks MJ. The epidemiology of chronic suppurative lung disease and bronchiectasis in children and adolescents. Front Pediatr 2017;5:27 10.3389/fped.2017.00027
    1. O’Grady KA, Revell A, Maguire GP, et al. . Lung health care for Aboriginal and Torres Strait Islander Queenslanders: breathing easy is not so easy. Aust Health Rev 2011;35:512–9. 10.1071/AH10973
    1. Basnayake TL, Morgan LC, Chang AB. The global burden of respiratory infections in indigenous children and adults: a review. Respirology 2017;22:1518–28. 10.1111/resp.13131
    1. Blackall SR, Hong JB, King P, et al. . Bronchiectasis in indigenous and non-indigenous residents of Australia and New Zealand. Respirology 2018;23:743–9. 10.1111/resp.13280
    1. Grimwood K, Fong SM, Ooi MH, et al. . Antibiotics in childhood pneumonia: how long is long enough? Pneumonia 2016;8:6 10.1186/s41479-016-0006-x
    1. Chang AB, Ooi MH, Perera D, et al. . Improving the diagnosis, management, and outcomes of children with pneumonia: where are the gaps? Front Pediatr 2013;1:29 10.3389/fped.2013.00029
    1. Grimwood K, Chang AB. Long-term effects of pneumonia in young children. Pneumonia 2015;6:101–14. 10.15172/pneu.2015.6/621
    1. Fox MP, Thea DM, Sadruddin S, et al. . Low rates of treatment failure in children aged 2-59 months treated for severe pneumonia: a multisite pooled analysis. Clin Infect Dis 2013;56:978–87. 10.1093/cid/cis1201
    1. Lassi ZS, Das JK, Haider SW, et al. . Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. Arch Dis Child 2014;99:687–93. 10.1136/archdischild-2013-304023
    1. Hazir T, Nisar YB, Abbasi S, et al. . Comparison of oral amoxicillin with placebo for the treatment of world health organization-defined nonsevere pneumonia in children aged 2-59 months: a multicenter, double-blind, randomized, placebo-controlled trial in pakistan. Clin Infect Dis 2011;52:293–300. 10.1093/cid/ciq142
    1. Ben-Shimol S, Levy-Litan V, Falup-Pecurariu O, et al. . Evidence for short duration of antibiotic treatment for non-severe community acquired pneumonia (CAP) in children — are we there yet? A systematic review of randomised controlled trials. Pneumonia 2014;4:16–23. 10.15172/pneu.2014.4/432
    1. Greenberg D, Givon-Lavi N, Sadaka Y, et al. . Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: a double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J 2014;33:136–42. 10.1097/INF.0000000000000023
    1. Kerrison C, Riordan FA. How long should we treat this infection for? Arch Dis Child Educ Pract Ed 2013;98:136–40. 10.1136/archdischild-2013-304135
    1. Chang AB, Redding GJ, Everard ML. Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008;43:519–31. 10.1002/ppul.20821
    1. Douros K, Alexopoulou E, Nicopoulou A, et al. . Bronchoscopic and high-resolution CT scan findings in children with chronic wet cough. Chest 2011;140:317–23. 10.1378/chest.10-3050
    1. Dimopoulos G, Poulakou G, Pneumatikos IA, et al. . Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013;144:1759–67. 10.1378/chest.13-0076
    1. Falagas ME, Vouloumanou EK, Matthaiou DK, et al. . Effectiveness and safety of short-course vs long-course antibiotic therapy for group a beta hemolytic streptococcal tonsillopharyngitis: a meta-analysis of randomized trials. Mayo Clin Proc 2008;83:880–9. 10.1016/S0025-6196(11)60764-7
    1. Paradise JL. Short-course antimicrobial treatment for acute otitis media: not best for infants and young children. JAMA 1997;278:1640–2.
    1. Hoberman A, Paradise JL, Rockette HE, et al. . Shortened antimicrobial treatment for acute otitis media in young children. N Engl J Med 2016;375:2446–56. 10.1056/NEJMoa1606043
    1. Keren R, Chan E. A meta-analysis of randomized, controlled trials comparing short- and long-course antibiotic therapy for urinary tract infections in children. Pediatrics 2002;109:e70 10.1542/peds.109.5.e70
    1. Singleton RJ, Valery PC, Morris P, et al. . Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol 2014;49:189–200. 10.1002/ppul.22763
    1. Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. Lancet 2018;392:866–79. 10.1016/S0140-6736(18)31554-X
    1. Chang AB, Marsh RL, Upham JW, et al. . Toward making inroads in reducing the disparity of lung health in Australian indigenous and new zealand māori children. Front Pediatr 2015;3:9 10.3389/fped.2015.00009
    1. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586 10.1136/bmj.e7586
    1. Nascimento-Carvalho CM, Madhi SA, O’Brien KL. Review of guidelines for evidence-based management for childhood community-acquired pneumonia in under-5 years from developed and developing countries. Pediatr Infect Dis J 2013;32:1281–2. 10.1097/INF.0b013e3182a4dcfa
    1. Chang AB, Masel JP, Boyce NC, et al. . Respiratory morbidity in central Australian Aboriginal children with alveolar lobar abnormalities. Med J Aust 2003;178:490–4.
    1. Goyal V, Grimwood K, Byrnes CA, et al. . Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2018;392:1197–206. 10.1016/S0140-6736(18)31723-9
    1. McCallum GB, Morris PS, Grimwood K, et al. . Three-weekly doses of azithromycin for indigenous infants hospitalized with bronchiolitis: a multicentre, randomized, placebo-controlled trial. Front Pediatr 2015;3:32 10.3389/fped.2015.00032
    1. McCallum GB, Morris PS, Chatfield MD, et al. . A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo-controlled trial. PLoS One 2013;8:e74316 10.1371/journal.pone.0074316
    1. Chang AB, Van Asperen PP, Glasgow N, et al. . Children with chronic cough: when is watchful waiting appropriate? development of likelihood ratios for assessing children with chronic cough. Chest 2015;147:745–53. 10.1378/chest.14-2155
    1. Valery PC, Morris PS, Byrnes CA, et al. . Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013;1:610–20. 10.1016/S2213-2600(13)70185-1
    1. Redding G, Singleton R, Lewis T, et al. . Early radiographic and clinical features associated with bronchiectasis in children. Pediatr Pulmonol 2004;37:297–304. 10.1002/ppul.10427
    1. Chang AB, Grimwood K, White AV, et al. . Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol. Trials 2011;12:94 10.1186/1745-6215-12-94
    1. Schulz KF, Altman DG, Consort MD. Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010;2010:32.
    1. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18 10.1016/S1473-3099(18)30310-4
    1. Chang AB, Oppenheimer JJ, Weinberger MM, et al. . Use of management pathways or algorithms in children with chronic cough: CHEST Guideline and expert panel report. Chest 2017;151:875–83. 10.1016/j.chest.2016.12.025
    1. Chang AB, Landau LI, Van Asperen PP, et al. . Cough in children: definitions and clinical evaluation. Med J Aust 2006;184:398–403.
    1. O’Grady KF, Drescher BJ, Goyal V, et al. . Chronic cough postacute respiratory illness in children: a cohort study. Arch Dis Child 2017;102:1044–8. 10.1136/archdischild-2017-312848
    1. Chang AB, Upham JW, Masters IB, et al. . Protracted bacterial bronchitis: the last decade and the road ahead. Pediatr Pulmonol 2016;51:225–42. 10.1002/ppul.23351
    1. Chang AB, Robertson CF, Van Asperen PP, et al. . A multicenter study on chronic cough in children: burden and etiologies based on a standardized management pathway. Chest 2012;142:943–50. 10.1378/chest.11-2725
    1. McCallum GB, Chatfield MD, Morris PS, et al. . Risk factors for adverse outcomes of Indigenous infants hospitalized with bronchiolitis. Pediatr Pulmonol 2016;51:613–23. 10.1002/ppul.23342
    1. Trenholme AA, Byrnes CA, McBride C, et al. . Respiratory health outcomes 1 year after admission with severe lower respiratory tract infection. Pediatr Pulmonol 2013;48:772–9. 10.1002/ppul.22661
    1. Marchant J, Masters IB, Champion A, et al. . Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax 2012;67:689–93. 10.1136/thoraxjnl-2011-201506
    1. Usonis V, Ivaskevicius R, Diez-Domingo J, et al. . Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines. Pneumonia 2016;8:5 10.1186/s41479-016-0005-y
    1. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013;1:262–74. 10.1016/S2213-2600(13)70038-9

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅